Automated insulin delivery systems are safe, effective, and well-received by older adults with type 1 diabetes, challenging ...

Sales Beat, Unexpected Profit. During the three months ended Dec. 31, Tandem Diabetes brought in $252.4 million in adjusted ...

New research from Washington State University in collaboration with five other institutions suggests that automated insulin ...

"The risk of diabetic ketoacidosis linked to continuous subcutaneous insulin infusion in type 1 diabetes has significantly ...

New research suggests that automated insulin delivery (AID) systems are safe and effective for use by older adults with type 1 diabetes. The findings counter common assumptions that older adults would ...

Why understanding the differences between Type 1 and Type 2 diabetes is essential for better health management and effective ...

An early-morning rise in blood sugar is common in people with diabetes. Find out more about why it happens and how to prevent ...

Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes.

Embecta's compelling ~44% free cash flow yield offers a strong risk-reward despite headwinds from new insulin technologies ...

Tandem Diabetes Care, Inc. reported strong Q4 2024 earnings, but shares declined 30%. Click for my TNDM stock update in light ...

Bernstein downgraded Tandem Diabetes (TNDM) to Market Perform from Outperform with a price target of $25, down from $35. The firm notes Tandem ...